Table 3.
Evaluation of risk for retinopathy, nephropathy and/or peripheral neuropathy by multivariate analyses
|
Parameter |
Univariate analysis |
Multivariate discriminant function analysis |
Multivariate regression analysis |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
(P-values) |
(P-values) |
(P-values) |
|||||||||||
| |
Retinopathy |
Nephropathy |
Neuropathy |
Retinopathy |
Nephropathy |
Neuropathy |
Microvascular diseases |
|||||||
| m | f | m | f | m | f | m | f | m | f | m | f | m | f | |
|
Duration T1DM |
0.021 |
0.043 |
0.253 |
0.553 |
0.079 |
0.098 |
0.000 |
0.000 |
0.330 |
0.534 |
0.049 |
0.041 |
0.000 |
0.001 |
|
BMI |
0.036 |
0.312 |
0.028 |
0.299 |
0.249 |
1.000 |
0.025 |
0.635 |
0.109 |
0.005 |
0.298 |
0.467 |
0.011 |
0.039 |
|
Total cholesterol |
0.352 |
0.246 |
0.439 |
0.017 |
0.750 |
0.041 |
0.021 |
0.019 |
0.017 |
0.426 |
0.958 |
0.522 |
0.002 |
0.666 |
|
LDL cholesterol |
0.252 |
0.031 |
0.393 |
0.052 |
0.264 |
0.500 |
0.184 |
0.022 |
0.074 |
0.015 |
0.465 |
0.537 |
0.023 |
0.084 |
|
HDL cholesterol |
0.405 |
0.032 |
0.052 |
0.383 |
0.247 |
0.659 |
0.106 |
0.018 |
0.038 |
0.589 |
0.695 |
0.511 |
0.002 |
0.640 |
|
Triglycerides |
0.049 |
0.049 |
0.421 |
0.040 |
0.149 |
0.169 |
0.009 |
0.029 |
0.178 |
0.273 |
0.263 |
0.578 |
0.007 |
0.732 |
|
Syst./Diast. RR |
0.005 |
0.006 |
0.000 |
0.002 |
0.806 |
0.637 |
0.940 |
0.141 |
0.223 |
0.797 |
0.657 |
0.867 |
0.621 |
0.483 |
| HbA1c | 0.536 | 0.005 | 0.150 | 0.998 | 0.212 | 1.000 | 0.315 | 0.082 | 0.780 | 0.265 | 0.238 | 0.315 | 0.381 | 0.453 |
Men (m), Women (f), Systolic/Diastolic blood pressure (Syst./Diast. RR).